Maria Tafelmeier

Dr. Maria Tafelmeier

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MTMaria Tafelmeier
Maria Tafelmeier
MKMarvin Knapp
Marvin Knapp
SLSimon Lebek
Simon Lebek
BFBernhard Floerchinger
Bernhard Floerchinger
DCDaniele Camboni
Daniele Camboni
MAMichael Arzt
Michael Arzt
Introduction: Delirium ranks among the most common complications after cardiac surgery. Although various risk factors have been identified, the association between sleep disordered breathing (SDB) and delirium has barely been examined so far. Here, our objectives were to determine the incidence of post-operative delirium and to identify the risk factors for delirium in patients with and without SDB.Methods: This subanalysis of the ongoing prospective observational study CONSIDER-AF (ClinicalTrials.govidentifierNCT02877745) examined risk factors for delirium in 141 patients undergoing cardiac surgery. The presence and type of SDB were assessed with a portable SDB monitor the night before surgery. Delirium was prospectively assessed with the validated Confusion Assessment Method for the Intensive Care Unit on the day of extubation and for a maximum of 3 days.Results: Delirium was diagnosed in 23% of patients: in 16% of patients without SDB, in 13% with obstructive sleep apnoea and in 49% with central sleep apnoea. Multivariable logistic regression analysis showed that delirium was independently associated with age ≥70 years (OR 5.63, 95% CI 1.79–17.68; p=0.003), central sleep apnoea (OR 4.99, 95% CI 1.41–17.69; p=0.013) and heart failure (OR 3.3, 95% CI 1.06–10.35; p=0.039). Length of hospital stay and time spent in the intensive care unit/intermediate care setting were significantly longer for patients with delirium.Conclusions: Among the established risk factors for delirium, central sleep apnoea was independently associated with delirium. Our findings contribute to identifying patients at high risk of developing post-operative delirium who may benefit from intensified delirium prevention strategies.

3 March 2020 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
MTMaria Tafelmeier
Maria Tafelmeier
ABAndrea Baessler
Andrea Baessler
SWStefan Wagner
Stefan Wagner
BUBernhard Unsoeld
Bernhard Unsoeld
APAndrej Preveden
Andrej Preveden
LMLars S. Maier
Lars S. Maier
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with a broad spectrum of disease severity. HCM ranges from a benign course to a progressive disorder characterized by angina, heart failure, malignant arrhythmia, syncope, or sudden cardiac death. So far, no medical treatment has reliably shown to halt or reverse progression of HCM or to alleviate its symptoms. While the angiotensin receptor neprilysin inhibitor sacubitril/valsartan has shown to reduce mortality and hospitalization in heart failure with reduced ejection fraction, data on its effect on HCM are sparse.Hypothesis: A 4‐month pharmacological (sacubitril/valsartan) or lifestyle intervention will significantly improve exercise tolerance (ie, peak oxygen consumption) in patients with nonobstructive HCM compared to the optimal standard therapy (control group).Methods: SILICOFCM is a prospective, multicenter, open‐label, randomized, controlled, three‐arm clinical trial (NCT03832660) that will recruit 240 adult patients with a confirmed diagnosis of nonobstructive HCM. Eligible patients are randomized to sacubitril/valsartan, lifestyle intervention (physical activity and dietary supplementation with inorganic nitrate), or optimal standard therapy alone (control group). The primary endpoint is the change in functional capacity (ie, peak oxygen consumption). Secondary endpoints include: (a) Change in cardiac structure and function as assessed by transthoracic echocardiography and cardiac magnetic resonance (MRI imaging), (b) change in biomarkers (ie, CK, CKMB, and NT‐proBNP), (c) physical activity, and (d) quality of life.Results: Until December 2019, a total of 41 patients were recruited into the ongoing SILICOFCM study and were allocated to the study groups and the control group. There was no significant difference in key baseline characteristics between the three groups.Conclusion: The SILICOFCM study will provide novel evidence about the effect of sacubitril/valsartan or lifestyle intervention on functional capacity, clinical phenotype, injury and stretch activation markers, physical activity, and quality of life in patients with nonobstructive HCM.

12 June 2018 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
MTMaria Tafelmeier
Maria Tafelmeier
TWTeresa Weizenegger
Teresa Weizenegger
SRSarah Ripfel
Sarah Ripfel
MFMiriam Fauser
Miriam Fauser
BFBernhard Floerchinger
Bernhard Floerchinger
MAMichael Arzt
Michael Arzt

1 February 2021 in Chest
Verified
Journal Article
Closed access
MTMaria Tafelmeier
Maria Tafelmeier
LLLili Luft
Lili Luft
EZElisabeth Zistler
Elisabeth Zistler
BFBernhard Floerchinger
Bernhard Floerchinger
DCDaniele Camboni
Daniele Camboni
MAMichael Arzt
Michael Arzt

22 February 2019 in Somnologie
Verified
Journal Article
Open access
PDF file
MTMaria Tafelmeier
Maria Tafelmeier
MKMarvin Knapp
Marvin Knapp
SLSimon Lebek
Simon Lebek
BFBernhard Floerchinger
Bernhard Floerchinger
DCDaniele Camboni
Daniele Camboni
MAMichael Arzt
Michael Arzt
The objectives of the CONSIDER AF (NCT02877745) observational study are to evaluate the impact of sleep-disordered breathing (SDB) on the rate of major adverse cardiac and cerebrovascular events in patients undergoing elective coronary artery bypass grafting (CABG) surgery. In addition, explorative analyses will allow specification of subgroups of patients with SDB with the highest risk for peri- and postoperative complications.

28 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MTMaria Tafelmeier
Maria Tafelmeier
VBVerka-Georgieva Blagoeva
Verka-Georgieva Blagoeva
MTMaximilian Trum
Maximilian Trum
Philipp HegnerPhilipp Hegner
Philipp Hegner
BFBernhard Floerchinger
Bernhard Floerchinger
MAMichael Arzt
Michael Arzt
Background: Nocturnal hypoxemia has been linked to increased cardiovascular morbidity and mortality. Several common diseases, such as sleep-disordered breathing (SDB), heart failure (HF), obesity, and pulmonary disease, coincide with an elevated nocturnal hypoxemic burden with and without repetitive desaturations. Research question: This study aimed to evaluate the association of relevant common diseases with distinctive metrics of nocturnal hypoxemic burden with and without repetitive desaturations in patients undergoing coronary artery bypass grafting surgery. Study design and methods: In this subanalysis of the prospective observational study, CONSIDER-AF (NCT02877745) portable SDB monitoring was performed on 429 patients with severe coronary artery disease the night before cardiac surgery. Pulse oximetry was used to determine nocturnal hypoxemic burden, as defined by total recording time spent with oxygen saturation levels < 90% (T90). T90 was further characterized as T90 due to intermittent hypoxemia (T90desaturation) and T90 due to nonspecific and noncyclic SpO2-drifts (T90non-specific). Results: Multivariable linear regression analysis identified SDB (apnea–hypopnea-index ≥ 15/h; B [95% CI]: 6.5 [0.4; 12.5], p = 0.036), obesity (8.2 [2.5; 13.9], p = 0.005), and mild-to-moderate chronic obstructive pulmonary disease (COPD, 16.7 [8.5; 25.0], p < 0.001) as significant predictors of an increased nocturnal hypoxemic burden. Diseases such as SDB, obesity and HF were significantly associated with elevated T90desaturation. In contrast, obesity and mild-to-moderate COPD were significant modulators of T90non-specific. Interpretation: SDB and leading causes for SDB, such as obesity and HF, are associated with an increased nocturnal hypoxemic burden with repetitive desaturations. Potential causes for hypoventilation syndromes, such as obesity and mild-to-moderate COPD, are linked to an increased hypoxemic burden without repetitive desaturations. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT02877745.